Genome-wide association studies (GWAS) have been performed for many psychiatric
disorders and revealed a complex polygenic architecture linking mental and physical health …

Genome-wide association studies (GWASs) have ushered in a new era of reproducible
discovery in psychiatric genetics. The field has now identified hundreds of common genetic …

The availability of genome-wide genetic data on hundreds of thousands of people has led to
an equally rapid growth in methodologies available to analyse these data. While the …

Psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder,
attention-deficit/hyperactivity disorder and autism spectrum disorder are common and result …

Genome-wide association studies have transformed psychiatric genetics and provided novel
insights into the genetic etiology of psychiatric disorders. Two major discoveries have …

Genome-wide association studies (GWAS) provide biological insights into disease onset
and progression and have potential to produce clinically useful biomarkers. A growing body …

Understanding which biological pathways are specific versus general across diagnostic
categories and levels of symptom severity is critical to improving nosology and treatment of …

Neuropsychiatric disorders, such as autism spectrum disorder (ASD), attention deficit
hyperactivity disorder (ADHD), schizophrenia (SCZ), bipolar disorder (BIP), and major …

Integrative approaches that harness large-scale molecular datasets can help develop
mechanistic insight into findings from genome-wide association studies (GWAS). We have …

Recent large-scale genetic approaches such as genome-wide association studies have
allowed the identification of common genetic variations that contribute to risk architectures of …